股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | - | 說明 | 非上市股份 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 288,616,500 | RMB | | 1 RMB | | 288,616,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 288,616,500 | RMB | | 1 RMB | | 288,616,500 | 本月底法定/註冊股本總額： RMB 399,398,420 FF301 第 1 頁 共 10 頁 v 1.1.1 公司名稱: 百奧賽圖(北京) ...

【环球网财经综合报道】百奥赛图（北京）医药科技股份有限公司作为聚焦基因编辑与抗体药物研发的生物医药企业，目前正在申请上市，然而结合公开资 料与前期披露信息，公司在人员变动、关联交易、信息披露、研发投入等方面存在争议。 人员锐减与研发缩水：经营可持续性遭质疑 百奥赛图研发团队规模的大幅收缩，成为市场质疑其经营稳定性的首要问题。公开数据显示，2022年8月，公司三个服务中心约有904名研发人员从事临床前 研究服务，涵盖基因编辑、临床前药理药效评估、模式动物销售、抗体开发等核心领域。但截至2024年末，公司研发人员仅剩337人，2年半时间内减少 63%，人员流失幅度远超行业平均水平。 从整体员工规模来看，公司同样呈现明显缩减趋势。2021年末至2024年末，员工总数从1392人降至1095人，其中2022年至2023年员工数量从1334人骤减至 1047人，一年之内减少287人。有观点认为，在生物医药行业高度依赖研发人才的背景下，如此大规模的人员流失，不仅可能导致核心技术传承断裂、研发 项目推进受阻，更引发市场对公司经营战略调整、业务收缩或资金压力的猜测，其经营可持续性亟待进一步说明。 | 专业类别 | 人数 | ...

Core Viewpoint - Baiaosaitu's IPO on the Sci-Tech Innovation Board was approved on September 24, aiming to raise 1.185 billion RMB for early drug research and development services [1][4]. Group 1: IPO and Market Reaction - Baiaosaitu's stock price rose over 10% on September 25 after the IPO approval, closing at 29.5 HKD per share, a 5.73% increase [1]. - The company completed its H-share IPO in September 2022, and if the Sci-Tech Innovation Board listing is successful, 77.81% of its shares will be traded on the A-share market [2]. Group 2: Financial Performance - For the first half of 2025, Baiaosaitu reported revenue of 621 million RMB, a 51.27% increase year-on-year, and a net profit of 48 million RMB, marking a turnaround from losses in the previous year [2][3]. - The company's preclinical product and service business, primarily from innovative animal model sales, generated revenue of 4.58 million RMB, up 56.9%, with a gross margin of approximately 70% [2]. Group 3: Fundraising and Investment Plans - The company plans to allocate the raised funds as follows: 38.28% for early drug research platform construction, 26.70% for antibody drug research and evaluation, 13.92% for preclinical research projects, and 21.10% for working capital [5]. - The projected revenue growth from 2022 to 2024 shows a compound annual growth rate of 35.56%, with net profits turning positive in 2024 [5]. Group 4: Research and Development Focus - Baiaosaitu has focused on gene editing technology since its establishment in 2009, developing four major technology platforms [4]. - The company aims to continue its "thousand mice, ten thousand antibodies" initiative, leveraging its gene editing platform to develop innovative mouse models for various diseases [10]. Group 5: Ownership Structure - As of the date of the prospectus, the company's major shareholders, Shen Yulei and Ni Jian, control 27.03% of the voting rights [6][9].

Group 1: Chery Automobile's IPO - Chery Automobile officially listed on the Hong Kong Stock Exchange on September 25, 2023, marking the largest IPO for a car company in Hong Kong this year [1] - The IPO price was set at HKD 30.75 per share, raising approximately HKD 9.145 billion [1] - Revenue is projected to grow from CNY 92.618 billion in 2022 to CNY 269.897 billion in 2024, with a compound annual growth rate (CAGR) of 70.7%, while net profit is expected to rise from CNY 5.806 billion to CNY 14.334 billion, with a CAGR of 57.1% [1] Group 2: Shandong Gold International's Listing - Shandong Gold International submitted its prospectus to the Hong Kong Stock Exchange, aiming for a main board listing [2] - The company is recognized as one of China's leading gold producers, focusing on the exploration and mining of gold, silver, lead, and zinc [2] - It is noted for having the strongest profitability and cost-effectiveness among listed gold companies in China, with a projected net profit growth of 48.43% year-on-year for the first half of 2025 [2] Group 3: Shuanglin Technology's IPO - Shuanglin Technology has filed for an IPO on the Hong Kong Stock Exchange, with CITIC Securities and GF Securities as joint sponsors [3] - The company specializes in manufacturing intelligent components for automotive drive systems and is the second-largest global supplier of horizontal drive mechanisms (HDM) for automotive seats, holding a 15.1% market share [3] - The funds raised from the IPO are expected to support overseas capacity expansion and technological research and development [3] Group 4: Baiaosaitu's A-Share Issuance Approval - Baiaosaitu received approval from the Shanghai Stock Exchange for its A-share issuance and listing on the Sci-Tech Innovation Board [4] - The company plans to issue up to 99.8496 million A-shares, with proceeds aimed at enhancing early drug research services, antibody drug development, and clinical research projects [4] - Baiaosaitu has shown significant revenue growth and has turned profitable, leveraging its proprietary antibody platform [4]

证券时报·数据宝统计显示，9月24日，上交所上市审核委员会2025年第38次审议会议结果公告显示，百 奥赛图(北京)医药科技股份有限公司(简称百奥赛图)首发申请获上市委会议通过。 公司基于自主开发的基因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务。本次发行保 荐机构为中国国际金融股份有限公司。公司拟发行股数9984.96万股，拟募集资金11.85亿元。 研发投入方面，近三年公司研发投入分别为6.99亿元、4.74亿元、3.24亿元，占营业收入比例分别为 130.96%、66.17%、33.04%。截至2024年12月31日，公司共有研发人员337人，占同期公司员工人数的 30.78%。（数据宝） 公司主要财务指标 | 财务指标/时间 | 2024年 | 2023年 | 2022年 | | --- | --- | --- | --- | | 营业收入（万元） | 98045.39 | 71691.18 | 53388.08 | | 归属母公司股东的净利润（万元） | 3354.18 | -38295.03 | -60194.47 | | 扣除非经常损益后归属母公司所有者净利润（万元） | 2296. ...

百奧賽圖 北京 醫藥科技股份有限公司 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (A joint stock company incorporated in the People's Republic of China with limited liability) （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） Stock code 股份代號：2315 INTERIM REPORT 中期報告 2025 目錄 CONTENTS | 2 | 公司資料 | Corporate Information | | --- | --- | --- | | 6 | 財務概要 | Financial Summary | | 7 | 管理層討論與分析 | Management Discussion and Analysis | | 50 | 企業管治及其他資料 | Corporate Governance and Other Information | | 75 | 審閱報告 | Review Report | | 77 | 綜合損益及其他 ...

智通财经APP获悉，百奥赛图-B(02315)早盘涨超5%，截至发稿，涨4.87%，报29.26港元，成交额636.36 万港元。 （原标题：港股异动 | 百奥赛图-B(02315)涨超5% 科创板IPO过会 近期连签默克、Tubulis等推进国际化 合作） 消息面上，百奥赛图公布，上交所科创板上市委员会2025年第38次审议会议已于9月24日召开。根据会 议审议结果，公司建议A股发行及于上交所科创板上市已获上交所科创板上市委员会批准。值得一提的 是，百奥赛图近期宣布先后与德国Tubulis及全球领先的科技公司默克达成合作协议。Tubulis拟引进百 奥赛图自主开发的全人抗体推进其ADC产品的研发和商业化。百奥赛图将获得一笔首付款，还将有权 获得开发、监管及商业化里程碑付款以及个位数净销售额分成。与默克的合作则聚焦于推进开发应用于 核酸药物的抗体偶联脂质递送解决方案，例如抗体偶联脂质纳米颗粒（LNP）。 ...

消息面上，百奥赛图公布，上交所科创板上市委员会2025年第38次审议会议已于9月24日召开。根据会 议审议结果，公司建议A股发行及于上交所科创板上市已获上交所科创板上市委员会批准。值得一提的 是，百奥赛图近期宣布先后与德国Tubulis及全球领先的科技公司默克达成合作协议。Tubulis拟引进百 奥赛图自主开发的全人抗体推进其ADC产品的研发和商业化。百奥赛图将获得一笔首付款，还将有权 获得开发、监管及商业化里程碑付款以及个位数净销售额分成。与默克的合作则聚焦于推进开发应用于 核酸药物的抗体偶联脂质递送解决方案，例如抗体偶联脂质纳米颗粒（LNP）。 智通财经APP获悉，百奥赛图-B(02315)早盘涨超5%，截至发稿，涨4.87%，报29.26港元，成交额636.36 万港元。 ...

Core Viewpoint - The company BaiO Saite-B (02315) has received approval from the Shanghai Stock Exchange's Sci-Tech Innovation Board for its A-share issuance and listing, which has positively impacted its stock price, leading to a rise of over 5% in early trading [1] Group 1: Stock Performance - BaiO Saite-B's stock price increased by 4.87%, reaching HKD 29.26, with a trading volume of HKD 6.36 million [1] Group 2: Corporate Developments - The Shanghai Stock Exchange's Sci-Tech Innovation Board Listing Committee approved BaiO Saite-B's proposal for A-share issuance and listing during its 38th review meeting on September 24, 2025 [1] - BaiO Saite-B has entered into collaboration agreements with Germany's Tubulis and global technology leader Merck. Tubulis aims to utilize BaiO Saite-B's self-developed fully human antibodies to advance its ADC product development and commercialization, providing BaiO Saite-B with an upfront payment and potential milestone payments along with a single-digit percentage of net sales [1] - The partnership with Merck focuses on developing antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [1]

格隆汇9月24日｜中国生物制药及临床前研究服务公司百奥赛图(2315.HK)公布，公司建议A股发行及于 上交所科创板上市，今日已获上交所科创板上市委员会批准。公司在2023年3月曾披露，建议向中国相 关监管机构申请发行不多于9984.96万股A股，并在科创板上市。A股发行所得款项将用于药物早期研发 服务平台建设项目、抗体药物研发及评价项目、临床前及临床研发项目及补充流动资金。 ...